Ulf Persson (Former)
1 – 20 of 51
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
(
- Contribution to journal › Article
- 2018
-
Mark
Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
(
- Contribution to journal › Article
-
Mark
Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
(
- Contribution to journal › Article
- 2016
-
Mark
Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
- 2014
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
(
- Contribution to journal › Article
-
Mark
Costs and Utilities of Manual Therapy and Orthopedic Standard Care for Low Prioritized Orthopedic Outpatients of Working Age: A Cost Consequence Analysis.
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
(
- Contribution to journal › Article
- 2013
-
Mark
Acute pancreatitis - costs for healthcare and loss of production.
(
- Contribution to journal › Article
- 2012
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
-
Mark
A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
(
- Contribution to journal › Article
-
Mark
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
(
- Contribution to journal › Article
-
Mark
Budget impact analysis of surgical treatment for obesity in sweden.
(
- Contribution to journal › Article
-
Mark
Drug and treatment costs in Parkinson's disease patients in Sweden.
(
- Contribution to journal › Article
- 2011
-
Mark
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
(
- Contribution to journal › Article